SECUKINUMAB SHOWS HIGHER SYMPTOMATIC IMPROVEMENT VERSUS INFLIXIMAB IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 1 YEAR ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISONS

被引：0
|
作者：
Strand, V [1 ]
McInnes, I. [2 ]
Thom, H. [3 ]
Hunger, M. [4 ]
Lopes, N. [5 ]
Gandhi, K. [6 ]
Jugl, S. M. [7 ]
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Univ Glasgow, Glasgow, Lanark, Scotland
[3] Univ Bristol, Bristol, Avon, England
[4] Mapi Grp, Munich, Germany
[5] Novartis Biociencias SA, Sao Paulo, Brazil
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Novartis Pharma AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2960
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS5
引用
收藏
页码：A935 / A936
页数：2
相关论文
共 37 条
  • [1] SECUKINUMAB SHOWS HIGHER SYMPTOMATIC IMPROVEMENT VERSUS ETANERCEPT IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 24 WEEKS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON
    Mease, P.
    Choy, E.
    Thom, H.
    Kalyvas, C.
    Lopes, N.
    Pricop, L.
    Gandhi, K.
    Jugl, S. M.
    Nash, P.
    VALUE IN HEALTH, 2017, 20 (09) : A936 - A936
  • [2] SECUKINUMAB PROVIDES HIGHER SYMPTOMATIC IMPROVEMENT VERSUS ADALIMUMAB IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 48 WEEKS ASSESSED BY TWO MATCHING-ADJUSTED INDIRECT COMPARISONS
    Thom, H.
    Hunger, M.
    Rosal, G. F.
    Gandhi, K.
    Jugl, S. M.
    Nash, P.
    VALUE IN HEALTH, 2017, 20 (09) : A935 - A935
  • [3] Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison
    Strand, Vibeke
    Mease, Philip J.
    McInnes, Iain B.
    Nash, Peter
    Thom, Howard
    Hunger, Matthias
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
    Strand, Vibeke
    Betts, Keith A.
    Mittal, Manish
    Song, Jinlin
    Skup, Martha
    Joshi, Avani
    RHEUMATOLOGY AND THERAPY, 2017, 4 (02) : 349 - 362
  • [5] Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
    Vibeke Strand
    Keith A. Betts
    Manish Mittal
    Jinlin Song
    Martha Skup
    Avani Joshi
    Rheumatology and Therapy, 2017, 4 : 349 - 362
  • [6] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
    Nash, Peter
    McInnes, Iain B.
    Mease, Philip J.
    Thom, Howard
    Hunger, Matthias
    Karabis, Andreas
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen M.
    RHEUMATOLOGY AND THERAPY, 2018, 5 (01) : 99 - 122
  • [7] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
    Peter Nash
    Iain B. McInnes
    Philip J. Mease
    Howard Thom
    Matthias Hunger
    Andreas Karabis
    Kunal Gandhi
    Shephard Mpofu
    Steffen M. Jugl
    Rheumatology and Therapy, 2018, 5 : 99 - 122
  • [8] Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison
    Nash, Peter
    McInnes, Iain B.
    Mease, Philip J.
    Choy, Ernest H.
    Thom, Howard
    Kalyvas, Chrysostomos
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [9] COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND INFLIXIMAB IN PSORIATIC ARTHRITIS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON USING PIVOTAL PHASE III CLINICAL TRIAL DATA
    Kaul, Arvind
    Strand, Vibeke
    McInnes, Lain
    Mease, Philip
    Choy, Ernest
    Nash, Peter
    Thom, Howard
    Kalyvas, Chrysostomos
    Gandhi, Kunal
    Pricop, Luminita
    Jugl, Steffen
    RHEUMATOLOGY, 2018, 57
  • [10] COMPARATIVE EFFECTIVENESS OF SECUKINUMAB AND INFLIXIMAB IN PSORIATIC ARTHRITIS ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISON USING PIVOTAL PHASE 3 CLINICAL TRIAL DATA
    Strand, V.
    McInnes, I.
    Mease, P.
    Choy, E.
    Nash, P.
    Thom, H.
    Kalyvas, C.
    Gandhi, K.
    Pricop, L.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 957 - 957
1234